アルガトロバン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2018/01/11 14:31:25」(JST)
[Wiki en表示]
Argatroban
|
Clinical data |
Trade names |
Argatroban |
AHFS/Drugs.com |
Monograph |
Routes of
administration |
intravenous |
ATC code |
|
Pharmacokinetic data |
Bioavailability |
100% (intravenous) |
Protein binding |
54% |
Metabolism |
hepatic |
Biological half-life |
39 and 51 minutes |
Identifiers |
IUPAC name
- (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-
[[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]
sulfonylamino]pentanoyl]-4-methyl-piperidine-2-
carboxylic acid
|
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
ECHA InfoCard |
100.166.378 |
Chemical and physical data |
Formula |
C23H36N6O5S |
Molar mass |
508.635 g/mol |
3D model (JSmol) |
|
SMILES
-
O=C(O)[C@@H]3N(C(=O)C(NS(=O)(=O)c1cccc2c1NCC(C2)C)CCC/N=C(\N)N)CC[C@@H](C)C3
|
InChI
-
InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1 N
-
Key:KXNPVXPOPUZYGB-IOVMHBDKSA-N N
|
NY (what is this?) (verify) |
Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.[1] In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in patients who have HIT or are at risk for developing it. In 2012, it was approved by the MHRA in the UK for anticoagulation in patients with heparin-induced thrombocytopenia Type II (HIT) who require parenteral antithrombotic therapy.[2]
Argatroban is given intravenously and drug plasma concentrations reach steady state in 1–3 hours.[3] Argatroban is metabolized in the liver and has a half-life of about 50 minutes. It is monitored by PTT. Because of its hepatic metabolism, it may be used in patients with renal dysfunction. (This is in contrast to lepirudin, a direct thrombin inhibitor that is primarily renally cleared).
Transitioning to warfarin in individuals with heparin induced thrombocytopenia
Argatroban is used as an anticoagulant in individuals with thrombosis and heparin induced thrombocytopenia. Often these individuals require long term anticoagulation. If warfarin is chosen as the long term anticoagulant, this poses particular challenges due to the falsely elevated prothrombin time and INR caused by argatroban. The combination of argatroban and warfarin may raise the INR to greater than 5.0 without a significant increased risk of bleeding complications.[4] One solution to this problem is to measure the chromogenic factor X level. A level < 40-45% typically indicates that the INR will be therapeutic (2-3) when the argatroban is discontinued.
References
- ^ Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40. PMID 16148288
- ^ http://www.pharmatimes.com/Article/12-07-03/UK_launch_for_Mitsubishi_s_blood_thinner_Exembol.aspx
- ^ Dhillon S. Argatroban: A Review of its Use in the Management of Heparin-Induced Thrombocytopenia. Am J Cardiovasc Drugs 2009; 9 (4): 261-82. Link text
- ^ Hursting MJ, Lewis BE, Macfarlane DE (2005). "Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia". Clin Appl Thromb Hemost. 11 (3): 279–87. doi:10.1177/107602960501100306. PMID 16015413.
External links
- GlaxoSmithKline's website on argatroban
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
|
Antiplatelet drugs |
Glycoprotein IIb/IIIa inhibitors |
- Abciximab
- Eptifibatide
- Orbofiban
- Roxifiban
- Sibrafiban§
- Tirofiban
|
ADP receptor/P2Y12 inhibitors |
- Thienopyridines
- Clopidogrel
- Prasugrel
- Ticlopidine
- Nucleotide/nucleoside analogs
- Cangrelor
- Elinogrel
- Ticagrelor
|
Prostaglandin analogue (PGI2) |
- Beraprost
- Iloprost
- Prostacyclin
- Treprostinil
|
COX inhibitors |
- Acetylsalicylic acid/Aspirin#
- Aloxiprin
- Carbasalate calcium
- Indobufen
- Triflusal
|
Thromboxane inhibitors |
- Thromboxane synthase inhibitors
- Dipyridamole (+ aspirin)
- Picotamide
- Terbogrel
- Receptor antagonists
|
Phosphodiesterase inhibitors |
- Cilostazol
- Dipyridamole
- Triflusal
|
Other |
- Cloricromen
- Ditazole
- Vorapaxar
|
|
Anticoagulants |
Vitamin K antagonists
(inhibit II, VII, IX, X) |
- Coumarins: Acenocoumarol
- Coumatetralyl
- Dicoumarol
- Ethyl biscoumacetate
- Phenprocoumon
- Warfarin#
- 1,3-Indandiones: Clorindione
- Diphenadione
- Phenindione
- Other: Tioclomarol
|
Factor Xa inhibitors
(with some II inhibition) |
Heparin group/
glycosaminoglycans/
(bind antithrombin) |
- Low molecular weight heparin
- Bemiparin
- Certoparin
- Dalteparin
- Enoxaparin
- Nadroparin
- Parnaparin
- Reviparin
- Tinzaparin‡
- Oligosaccharides
- Fondaparinux
- Idraparinux§
- Heparinoids
- Danaparoid
- Dermatan sulfate
- Sulodexide
|
Direct Xa inhibitors ("xabans") |
- Apixaban
- Betrixaban
- Darexaban§
- Edoxaban
- Otamixaban§
- Rivaroxaban
|
|
Direct thrombin (IIa) inhibitors |
- Bivalent: Hirudin
- Bivalirudin
- Desirudin
- Lepirudin
- Univalent: Argatroban
- Dabigatran
- Efegatran
- Inogatran§
- Melagatran‡
- Ximelagatran‡
|
Other |
- Antithrombin III
- Defibrotide
- Protein C
- Ramatroban
- REG1
|
|
Thrombolytic drugs/
fibrinolytics |
- Plasminogen activators: r-tPA
- Alteplase
- Reteplase
- Tenecteplase
- UPA
- Anistreplase
- Monteplase
- Streptokinase#
- Other serine endopeptidases: Ancrod
- Brinase
- Fibrinolysin
|
Non-medicinal |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
Prostanoid signaling modulators
|
Receptor
(ligands) |
|
Enzyme
(inhibitors) |
COX
(PTGS) |
|
PGD2S |
- Retinoids
- Selenium (selenium tetrachloride, sodium selenite, selenium disulfide)
|
PGES |
HQL-79
|
PGFS |
Bimatoprost
|
PGI2S |
Tranylcypromine
|
TXAS |
- Camonagrel
- Dazmegrel
- Dazoxiben
- Furegrelate
- Isbogrel
- Midazogrel
- Nafagrel
- Nicogrelate
- Ozagrel
- Picotamide
- Pirmagrel
- Ridogrel
- Rolafagrel
- Samixogrel
- Terbogrel
- U63557A
|
|
Others |
- Precursors: Linoleic acid
- γ-Linolenic acid (gamolenic acid)
- Dihomo-γ-linolenic acid
- Diacylglycerol
- Arachidonic acid
- Prostaglandin G2
- Prostaglandin H2
|
- See also
- Receptor/signaling modulators
- Leukotriene signaling modulators
- Nuclear receptor modulators
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Development of a stent capable of the controlled release of basic fibroblast growth factor and argatroban to treat cerebral aneurysms: In vitro experiment and evaluation in a rabbit aneurysm model.
- Arai D1,2, Ishii A1, Ikeda H1, Abekura Y1, Nishi H1, Miyamoto S1, Tabata Y2.
- Journal of biomedical materials research. Part B, Applied biomaterials.J Biomed Mater Res B Appl Biomater.2019 Jan 17. doi: 10.1002/jbm.b.34314. [Epub ahead of print]
- PMID 30653829
- [Extracorporeal Membrane Oxygenation in Thoracic Surgery: the Anesthesiologist's Perspective].
- Rehers S1, Beiderlinden M2, Ziegeler S1.
- Zentralblatt fur Chirurgie.Zentralbl Chir.2019 Jan 8. doi: 10.1055/a-0774-8151. [Epub ahead of print]
- PMID 30620971
- Attenuation of type-1 diabetes-induced cardiovascular dysfunctions by direct thrombin inhibitor in rats: a mechanistic study.
- Bulani Y1, Srinivasan K1, Sharma SS2.
- Molecular and cellular biochemistry.Mol Cell Biochem.2019 Jan;451(1-2):69-78. doi: 10.1007/s11010-018-3394-9. Epub 2018 Jul 3.
- PMID 29971544
Japanese Journal
- 肝動注用カテーテル留置術後に肺塞栓を発症したヘパリン起因性血小板減少症の1例
- 古田 陽輝,工藤 康一,多田 修治,杉原 一明,泉 和寛,門野 義弘,上川 健太郎,近澤 秀人,今村 治男
- 日本消化器病學會雜誌 = The Japanese journal of gastro-enterology 109(6), 944-951, 2012-06-05
- 症例は68歳の女性.進行肝細胞癌に対して肝動注化学療法開始後,急性肺塞栓を発症した.血小板数の著明な低下を認め,動注時の使用ヘパリンによるヘパリン起因性血小板減少症を疑った.経過中,抗血小板第4因子・ヘパリン複合体抗体陽性が判明し,確定診断に至った.治療はヘパリン投与中止と,アルガトロバンによる抗血栓療法を施行した.さらに留置したヘパリン化親水性カテーテルの抜去を行い,血小板数の改善を認めた.
- NAID 10030651431
- 抗体陰性化を確認後にもかかわらず,ヘパリン再投与によりヘパリン起因性血小板減少症(heparin-induced thrombocytopenia : HIT)を再発した1例
Related Links
- • argatrobanには解毒剤は存 ~しないが,投与を中止して4-6 時間でAPTTがbaselineまで戻る 26 まとめ •脳梗塞や慢性動脈閉塞症の機能改善に関する海外 のエビデンスは乏しい •HITに対する抗凝固療法の有用性は高く,推奨される ...
- Argatroban is a white, odorless crystalline powder that is freely soluble in glacial acetic acid, slightly soluble in ethanol, and insoluble in acetone, ethyl acetate, and ether. Argatroban Injection is a sterile clear, colorless to pale yellow ...
Related Pictures
![Argatroban Intravenous : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing](https://1mg.info/0/v/n/2869.jpg)
![100 mg/mL Allopathic Argatroban Injection, Intravenous, 100 mg/mL, | ID: 11155667188](https://1mg.info/0/v/n/2870.jpg)
![Argatroban In Sodium Chloride (Iso-Osmotic) Intravenous : Uses, Side Effects](https://1mg.info/0/v/n/2871.jpg)
![Argatroban Intravenous : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing](https://1mg.info/0/v/n/2872.jpg)
![Argatroban Intravenous : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing](https://1mg.info/0/v/n/2873.jpg)
![Argatroban In Sodium Chloride (Iso-Osmotic) Intravenous : Uses, Side Effects](https://1mg.info/0/v/n/2874.jpg)
![argatroban intravenous : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing](https://1mg.info/0/v/n/2875.jpg)
★リンクテーブル★
[★]
- 英
- argatroban
- 商
- アルガロン、ガルトバン、スロンノン、スロンノンHI、ノバスタン、ノバスタンHI
- 関
- その他の循環器官用薬